• English

    Google Translate Disclaimer

    The Maryland Department of Information Technology (“DoIT”) offers translations of the content through Google Translate. Because Google Translate is an external website, DoIT does not control the quality or accuracy of translated content. All DoIT content is filtered through Google Translate which may result in unexpected and unpredictable degradation of portions of text, images and the general appearance on translated pages. Google Translate may maintain unique privacy and use policies. These policies are not controlled by DoIT and are not associated with DoIT’s privacy and use policies. After selecting a translation option, users will be notified that they are leaving DoIT’s website. Users should consult the original English content on DoIT’s website if there are any questions about the translated content.

    DoIT uses Google Translate to provide language translations of its content. Google Translate is a free, automated service that relies on data and technology to provide its translations. The Google Translate feature is provided for informational purposes only. Translations cannot be guaranteed as exact or without the inclusion of incorrect or inappropriate language. Google Translate is a third-party service and site users will be leaving DoIT to utilize translated content. As such, DoIT does not guarantee and does not accept responsibility for, the accuracy, reliability, or performance of this service nor the limitations provided by this service, such as the inability to translate specific files like PDFs and graphics (e.g. .jpgs, .gifs, etc.).

    DoIT provides Google Translate as an online tool for its users, but DoIT does not directly endorse the website or imply that it is the only solution available to users. All site visitors may choose to use alternate tools for their translation needs. Any individuals or parties that use DoIT content in translated form, whether by Google Translate or by any other translation services, do so at their own risk. DoIT is not liable for any loss or damages arising out of, or issues related to, the use of or reliance on translated content. DoIT assumes no liability for any site visitor’s activities in connection with use of the Google Translate functionality or content.

    The Google Translate service is a means by which DoIT offers translations of content and is meant solely for the convenience of non-English speaking users of the website. The translated content is provided directly and dynamically by Google; DoIT has no direct control over the translated content as it appears using this tool. Therefore, in all contexts, the English content, as directly provided by DoIT is to be held authoritative.

    Haemophilus influenzae type b (Hib) Disease
    Fact Sheet

    PDF Version of this Fact Sheet

    Haemophilus influenzae type b (Hib) is a bacterium that causes serious infections.

    Before the advent of effective vaccines, Hib was the most common cause of bacterial meningitis in children in the United States as well as in many other countries.  Since 1988, when the Hib vaccines were introduced, the rate of invasive Hib disease has decline by 99% in infants and young children.  When disease occurs, it usually is in children 2 months to 5 years of age.  Hib and types of Haemophilus influenzae other than type b can cause disease in elderly persons with underlying health conditions.  Hib can cause meningitis (inflammation of the brain and spinal cord covering) and other infections such as pneumonia (lung infection), ear, skin, joint, and blood infections.

    Hib is spread from person-to-person by airborne droplets and direct contact with infected respiratory secretions.

    Hib is carried in the nose or throat of children and adults who are infected.  It is possible for people who are not ill to carry Hib and spread it to others.  It is then spread to the next person through contact with discharge or droplets from the nose or mouth. 

    Symptoms to look for include:

    • Meningitis
    • Fever
    • Stiff neck
    • Drowsiness
    • Extreme irritability
    • Sudden vomiting
    • Other Hib infections
    • Symptoms at site of infection (for example: skin or joint redness, tenderness, or swollen area)

    The time period between when someone is exposed to Hib and when symptoms develop is unknown, but may be as short as 2 to 4 days.

    Laboratory testing is available to confirm a Hib infection. 

    People who think they may have Hib disease should see a doctor or their local health department.  Hib disease is diagnosed by testing the blood, spinal fluid, middle ear, and other bodily fluids.  See a doctor immediately for treatment.

    Treatment with antibiotics should be started immediately to stop the infection from causing serious complications or death.

    Certain people in close contact with someone who has Hib disease should receive treatment as well. 
    In specific situations, such as childcare settings, people who have been exposed to someone with Hib may be given a drug called rifampin to prevent getting or spreading Hib.  Rifampin is not recommended for pregnant women.  High risk contacts include: 

    • Persons who are 4 years of age and younger who are unimmunized or incompletely immunized;
    • Children younger than 12 months of age who have not received the primary series of vaccine
    • ; or
    • Immunocom
    • promised children regardless of the child’s Hib immunization status. 

    Hib disease can be prevented with Hib vaccine.

    Hib vaccine is recommended for all children starting at 2, 4, 6 and 15 months of age.  Hib vaccine is recommended for all children under 5 years of age who have not been previously immunized, and others may need Hib vaccine if they are at an increased risk for disease.  Age appropriate vaccination against Hib is required for entry into Maryland childcare institutions and schools. For additional information about Hib vaccine, please visit: http://www.cdc.gov/vaccines/vpd-vac/hib/default.htm